BPC-157

Overview

BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a fragment of body protection compound, a protein isolated from human gastric juice. It is research-only and not approved by the FDA or any major regulator for human use; almost all published evidence comes from rodent models.

Mechanism of Action

Preclinical studies suggest BPC-157 promotes angiogenesis and granulation tissue formation via upregulation of VEGFR2 signaling and activation of the FAK-paxillin pathway in tendon fibroblasts. It also modulates the nitric oxide system and interacts with dopaminergic and serotonergic pathways along the gut-brain axis. A precise receptor target has not been established.

Research Summary

Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage. Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses commonly used on the grey market.

Dosing Information

Reported Side Effects

• Nausea (especially oral)
• Dizziness or lightheadedness
• Injection site irritation
• Headache
• Note: the human side-effect profile is not well characterized in peer-reviewed literature

Labs to monitor before & during your BPC-157 protocol

These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.

Commonly Stacked With

Research References

• Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. 2011. PMID 21548867.
• Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. 2014. PMID 25415472.
• Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. 2019. PMID 30915550.
• Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. 2011. PMID 21030672.